Login to Your Account



FDA rejects Abilify with ingestible sensor; asks for more data

By Varun Saxena
Contributing Writer

Wednesday, April 27, 2016

A joint bid to deploy Proteus Digital Health Inc.'s ingestible sensor with Tokyo-based Otsuka Pharmaceutical Co. Ltd.'s antipsychotic drug, Abilify, was met with a complete response letter from the FDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription